Dupixent (dupilumab) now publicly reimbursed in Ontario and New Brunswick for the treatment of moderate to severe atopic dermatitis


25 May 2021 - Dupixent is the only biologic medicine approved by Health Canada to treat moderate to severe atopic dermatitis.

Sanofi Canada is pleased to announce that Ontario and New Brunswick have listed Dupixent (dupilumab) on their respective provincial drug programs for the treatment of moderate-to-severe atopic dermatitis for Canadians aged 12 years and older when specific criteria are met.

Read Sanofi press release

Michael Wonder

Posted by:

Michael Wonder